Press release
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies
NanoViricides, Inc., a clinical-stage biotechnology company, is revolutionizing the fight against viral diseases with its proprietary nanomedicine platform. At the forefront of their research is NV-387, a broad-spectrum antiviral drug that promises to address a wide range of critical viral infections, including COVID-19, respiratory syncytial virus (RSV), influenza, and Mpox/smallpox. This innovative solution underscores NanoViricides' commitment to advancing antiviral therapies and meeting significant unmet medical needs globally.
NV-387: A Disruptive Antiviral Technology
NV-387 exemplifies NanoViricides' innovative approach to antiviral therapy. The drug leverages a novel "Re-Infection Blocker" mechanism that mimics natural human cellular structures to directly neutralize viruses. This strategy prevents the virus from binding to healthy cells, halting its ability to replicate and spread. Unlike traditional treatments that target specific viral proteins, NV-387's mechanism is effective across a broad spectrum of viruses, including those with mutating strains, making it a versatile and highly adaptive solution
In preclinical studies, NV-387 demonstrated remarkable efficacy, surpassing established antiviral drugs like Tamiflu Registered and Xofluza Registered in treating influenza. It also completely cured lethal RSV infections in animal models, which is particularly significant as no approved treatment currently exists for RSV
These results highlight the drug's potential as a groundbreaking solution to combat some of the most persistent and dangerous viral diseases.
Addressing Critical Unmet Needs in RSV Treatment
Image: https://www.abnewswire.com/uploads/c716f7b6c36beefab6e264bc2f59bc23.jpg
RSV poses a severe health threat, especially to infants, the elderly, and immunocompromised individuals. Despite its prevalence, the market has lacked a safe and effective treatment option. NV-387 has shown immense promise in addressing this unmet need. In animal models, the drug not only ensured survival but also prevented lung damage, a critical advancement in RSV therapy.
The pediatric RSV treatment market alone is projected to be worth billions of dollars annually in the United States. With NV-387's advancement into Phase II clinical trials, NanoViricides is positioned to tap into this lucrative market while providing life-saving treatment to vulnerable populations
A Versatile Solution for Pandemic Preparedness
The COVID-19 pandemic underscored the need for rapid-response antiviral therapies capable of addressing emerging viral threats. NV-387's broad-spectrum efficacy makes it a vital tool for pandemic preparedness. Its ability to neutralize multiple viruses, including novel and mutating strains, positions it as a cornerstone of global healthcare defense systems.
Unlike vaccines, which target specific viral proteins prone to mutation, NV-387 disrupts the virus's entry mechanism, rendering it effective regardless of genetic variations. This adaptability ensures its utility in combating not only existing viruses but also future pandemics
Broadening the Pipeline: NanoViricides' Holistic Vision
Beyond NV-387, NanoViricides is developing a range of nanomedicine-based antiviral therapies targeting diverse diseases. These include:
1.Herpes Virus Treatments: NV-HHV-1 is being designed to address shingles, cold sores, and genital herpes.
2.Influenza Variants: NV-387 has shown strong efficacy against H1N1 and H5N1 strains in preclinical studies.
3.Future Viral Threats: The platform is flexible enough to adapt to emerging viruses, including dengue, rabies, and Ebola.
NanoViricides' approach emphasizes addressing global health challenges comprehensively. By targeting a wide range of viral diseases, the company is creating a pipeline that combines versatility with efficacy.
Collaborations and Funding
NanoViricides' success in advancing NV-387 is supported by strategic collaborations and innovative funding mechanisms. Partnering with Karveer Meditech Pvt. Ltd. in India, the company conducted successful Phase I clinical trials, establishing the drug's safety and tolerability
Moving forward, NanoViricides plans to expand its clinical trials to additional indications, including influenza and long COVID. To support these developments, the company is pursuing non-dilutive funding options such as grants and partnerships. This approach ensures sustainable growth while advancing its groundbreaking therapies
NV-387's Regulatory Pathway
The regulatory journey for NV-387 is well-defined, with Phase II clinical trials focusing on RSV in adults as a precursor to pediatric approval. Additionally, NanoViricides aims to explore the drug's potential in other viral indications, including Mpox and smallpox. This strategic progression aligns with the company's mission to deliver life-changing therapies to patients globally
Leadership Perspective
Dr. Anil Diwan, President and Executive Chairman of NanoViricides, views NV-387 as a revolutionary development in antiviral medicine. "Our goal is to address the greatest challenge in antiviral therapy-viral resistance. With NV-387, we have created a drug that viruses are highly unlikely to escape, paving the way for a new era in infectious disease treatment," Dr. Diwan stated.
Shaping the Future of Antiviral Medicine
Image: https://www.abnewswire.com/uploads/d3d6d860d1723ff56f1b02dcd1547ab6.jpg
NanoViricides' innovative nanomedicine platform and its lead drug candidate, NV-387, are poised to reshape the landscape of antiviral therapies. By addressing critical unmet needs and preparing for future pandemics, the company is setting a new standard in global healthcare.
For more information about NanoViricides and its groundbreaking research, visit their official website [https://www.nanoviricides.com/].
NanoViricides' advancements in antiviral therapy signify a paradigm shift in how viral diseases are treated. With NV-387 leading the charge, the company continues to pioneer solutions that hold the promise of improving millions of lives worldwide.
https://www.nanoviricides.com/
https://profiles.smallcapsdaily.com/nnvc/
Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.
Media Contact
Company Name: EDM Media
Contact Person: Steve Sandifer
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nanoviricidesamexnnvc-leads-innovation-in-broadspectrum-antiviral-therapies]
Phone: +1-214-435-3758
Address:1750 N. Collins Blvd. Suite 101-V
City: Richardson
State: TX 75080
Country: United States
Website: https://www.nanoviricides.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies here
News-ID: 3757738 • Views: …
More Releases from ABNewswire
S. Feldman Housewares Serves New Yorkers In The Upper West Side With Kitchen Sup …
For 96 years, S. Feldman Housewares has been a trusted resource for Manhattan families seeking quality kitchen supplies, home goods, and hardware. Located at 1304 Madison Avenue, this fourth-generation, family-owned store serves customers throughout the city, including Upper West Side residents who appreciate shopping at a trusted hardware store Upper West Side families have relied on for nearly a century.
New York, NY - February 23, 2026 - S. Feldman Housewares…
Country Creek Animal Hospital Broadens Veterinarian Offerings Across Allen, TX, …
Country Creek Animal Hospital remains committed to providing dependable, locally focused care for pets and their owners throughout Allen and Plano. Through steady service growth and a focus on accessibility, Country Creek Animal Hospital continues to support community trust, reliable care standards, and meaningful relationships with the families it serves.
Introduction: Expanding Veterinarian Care in Allen, TX
Country Creek Animal Hospital continues to strengthen its role as a dependable veterinarian [https://www.countrycreekvets.com/#:~:text=The%20best-,veterinarian,-in%20Allen%2C%20TX] provider…
Country Creek Animal Hospital Strengthens Veterinarian Support in Allen, TX, Ext …
Country Creek Animal Hospital continues to support pet owners across Allen and Frisco by focusing on dependable care, consistent service coverage, and community-centered values. Through thoughtful growth and operational improvements, Country Creek Animal Hospital remains dedicated to providing reliable veterinary support that meets local needs while maintaining the trust of the families it serves.
Introduction: Expanding Vet Clinic Support in Allen, TX
Country Creek Animal Hospital continues to reinforce its role as…
Kids Dentist in Las Vegas and Centennial Offers Pain-Free, Needle-Free Laser Den …
Desert Kids Dental, led by pediatric dentist Dr. Sandra Thompson, is redefining the dental experience for children in Centennial and Las Vegas by offering advanced Solea Registered Laser dentistry, a modern technology designed to deliver truly pain-free and needle-free dental care. As a trusted Kids Dentist serving local families, Desert Kids Dental continues to focus on comfort, efficiency, and positive experiences for children of all ages.
For many children and parents…
More Releases for NanoViricides
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNC …
"NV-387, as an effective drug would be an important tool to fight Measles resurgence in the USA and worldwide, when approved," said Anil R. Diwan, PhD, adding, "Treating a patient and providing the drug prophylactically to contacts would eliminate the need for quarantine and loss of valuable school time. An Orphan Drug Designation would help us tremendously in the mission of regulatory development and approval of NV-387 to treat Measles."
In…
NanoViricides Reports NV-387's Anti-Inflammatory Effects Could Combat Viral-Indu …
NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place," said Anil R. Diwan, Ph.D., President and Chairman, adding, "NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on…
NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotec …
NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs.
NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat viral infections-potentially creating the first "empiric antiviral therapy"…
Nanomedicines Market Prediction and Analysis Offered By New Study | Abbott, GE H …
The primary goal of the Nanomedicines Market report is to provide readers with a low-cost understanding of the industry that has been examined utilising primary and secondary research methods. This Nanomedicines Market report's primary goal is to provide a comprehensive overview and strategic analysis of the parent industry. The research comprehensively analyses each segment as well as any associated sub-segments that are present in the market. By analysing the market's…
Ebola Treatment Market Projected to Show Strong Growth | GlaxoSmithKline, NanoVi …
HTF MI Analyst have added a new research study on Title Ebola Treatment Market - Global Outlook and Forecast 2021-2027 with detailed information of Product Types [Vaccine (Under Trials) & Drugs (Under Trials)], Applications [Hospitals, Ambulatory Surgery Centres, Specialized Clinics & Army Camps (Veteran Facilities)] & Key Players Such as Arbutus Biopharma, GlaxoSmithKline, Johnson & Johnson Services, Hemispherx Biopharma, BioCryst Pharmaceuticals, NanoViricides, NewLink Genetics, Chimerix, Sarepta Therapeutics & Mapp Biopharmaceutical…
Investigation announced for NYSE: NNVC shares over potential Wrongdoing at NanoV …
An investigation on behalf of investors in shares of NanoViricides, Inc. (NYSE: NNVC) was announced over potential breaches of fiduciary duties by certain officers and directors at NanoViricides, Inc.
Investors who purchased shares of NanoViricides, Inc. (NYSE: NNVC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain NanoViricides, Inc. (NYSE: NNVC officers and directors…
